Clinical Trials Directory

Trials / Conditions / Metastatic Ureter Urothelial Carcinoma

Metastatic Ureter Urothelial Carcinoma

11 registered clinical trials studyying Metastatic Ureter Urothelial Carcinoma.

StatusTrialSponsorPhase
Active Not RecruitingTesting Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemo
NCT04963153
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTesting the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in
NCT05092958
National Cancer Institute (NCI)Phase 3
Active Not RecruitingTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594
Alliance for Clinical Trials in OncologyPhase 3
Active Not RecruitingTocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or
NCT04940299
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingARID1A and/or KDM6A Mutation and CXCL13 Expression
NCT04953104
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingImmune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
NCT04848519
Emory UniversityPhase 2
WithdrawnAdoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable o
NCT03935347
Roswell Park Cancer InstitutePhase 2
CompletedAtezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C
NCT03513952
National Cancer Institute (NCI)Phase 2
Active Not RecruitingAtezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metasta
NCT03237780
National Cancer Institute (NCI)Phase 2
CompletedCisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Uroth
NCT02567409
National Cancer Institute (NCI)Phase 2
CompletedGemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary
NCT00942331
National Cancer Institute (NCI)Phase 3